IL284850A - Methods of treating breast cancer with toctinib - Google Patents

Methods of treating breast cancer with toctinib

Info

Publication number
IL284850A
IL284850A IL284850A IL28485021A IL284850A IL 284850 A IL284850 A IL 284850A IL 284850 A IL284850 A IL 284850A IL 28485021 A IL28485021 A IL 28485021A IL 284850 A IL284850 A IL 284850A
Authority
IL
Israel
Prior art keywords
tucatinib
methods
breast cancer
treating breast
treating
Prior art date
Application number
IL284850A
Other languages
English (en)
Hebrew (he)
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of IL284850A publication Critical patent/IL284850A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL284850A 2019-01-28 2021-07-14 Methods of treating breast cancer with toctinib IL284850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (1)

Publication Number Publication Date
IL284850A true IL284850A (en) 2021-08-31

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284850A IL284850A (en) 2019-01-28 2021-07-14 Methods of treating breast cancer with toctinib

Country Status (13)

Country Link
US (1) US20220193076A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523045A (cg-RX-API-DMAC7.html)
KR (1) KR20210119498A (cg-RX-API-DMAC7.html)
CN (1) CN113613656A (cg-RX-API-DMAC7.html)
AR (1) AR119681A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020215551A1 (cg-RX-API-DMAC7.html)
CA (1) CA3126279A1 (cg-RX-API-DMAC7.html)
IL (1) IL284850A (cg-RX-API-DMAC7.html)
MX (1) MX2021008834A (cg-RX-API-DMAC7.html)
SG (1) SG11202107488PA (cg-RX-API-DMAC7.html)
TW (1) TW202042820A (cg-RX-API-DMAC7.html)
WO (1) WO2020159822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
IL301405A (en) * 2020-09-28 2023-05-01 Seagen Inc Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Also Published As

Publication number Publication date
SG11202107488PA (en) 2021-08-30
EP3917533A1 (en) 2021-12-08
CN113613656A (zh) 2021-11-05
JP2022523045A (ja) 2022-04-21
US20220193076A1 (en) 2022-06-23
CA3126279A1 (en) 2020-08-06
TW202042820A (zh) 2020-12-01
KR20210119498A (ko) 2021-10-05
AR119681A1 (es) 2022-01-05
MX2021008834A (es) 2021-09-28
WO2020159822A1 (en) 2020-08-06
AU2020215551A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL289297A (en) Adjuvant treatment for her2-positive breast cancer
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL277981A (en) Cancer treatment methods
ZA201902454B (en) Lasofoxifene treatment of er+ breast cancer
SI3826667T1 (sl) Protitelesa Claudin6 in metode zdravljenja raka
IL266324A (en) Treatment of her2-positive breast cancer
IL266917A (en) Methods for treating prolactin receptor-positive breast cancer
SG11202011117VA (en) Treatment of cancer
IL281600B2 (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
SG11202107017TA (en) Methods of treating cancer
IL289811A (en) A method for treating cancer
IL279591A (en) Cancer treatment methods using combination therapy
GB201820098D0 (en) Methods of cancer treatment
SG11202005163PA (en) Methods of treating cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
IL269123A (en) Methods of treating cancer
PL3302551T3 (pl) Sposoby leczenia HER2-dodatniego, wcześniej nieleczonego przerzutowego raka sutka
PT4003533T (pt) Métodos de tratamento de cancro multifocal
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
IL269295A (en) Methods of treating breast cancer
HK40063537A (en) Methods of treating breast cancer with tucatinib